P53 immunoreactivity tested by IHC, an alternative method of TP53 mutation testing, was observed as an overexpression in pancreatic NECs, and negative or lower expression was detected in pancreatic NETs. This evidence concerns the gene TP53 and pancreatic endocrine carcinoma.